Copyright 2016 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
The use of prostate-specific antigen (PSA) screening for prostate cancer is controversial. Various organizations have released conflicting messages regarding the use of the PSA screening test. In 2012, the US Preventive Services Task Force recommended against routine PSA screening, citing a lack of evidence regarding its benefits and known harms from prostate biopsy and overtreatment of indolent prostate cancer.1
Aaronson DS, Redberg RF. Use of Prostate-Specific Antigen Testing Is in the Eye of the Beholder. JAMA Intern Med. 2016;176(4):547-548. doi:10.1001/jamainternmed.2015.8104